Jpmorgan Chase & CO Aim Immuno Tech Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AIM
# of Institutions
37Shares Held
8.42MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.08MShares$1.02 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$497,1760.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$174,5660.0% of portfolio
-
Geode Capital Management, LLC Boston, MA401KShares$100,2560.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny229KShares$57,2020.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $12M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...